Overdiagnosed: How Profit Reshaped ADHD Care
From original sources
About this Capsule
Rising ADHD diagnoses track less with patient need than with an industry that profits from every prescription. Against the mainstream default of medication first, this take says drug-company influence biases research and guidelines, and that community-based and behavioral approaches address root causes without pathologizing normal behavior. Skepticism toward profit-driven diagnosis is the starting point for more honest mental health care.
Questions this capsule answers
Tap any question to get it answered inside the capsule, free.
Generic AI vs AI with This Capsule
Preview“Why do ADHD diagnosis rates vary so wildly between states and countries if it's a biological brain disorder?”
Generic AI
“ADHD can be a biologically based neurodevelopmental disorder and still have diagnosis rates that vary widely. The key is that “ADHD diagnosis rate” is not the same thing as “true underlying rate of ADHD traits in the population.”
Several things affect whether a person with ADHD-like impairments actually gets diagnosed:
1. No simple biological test
ADHD is associated with brain development, genetics, dopamine/norepinephrine systems, executive function, etc., but diagnosis is still based on behavior, impairment, history, and context, not a blood test or brain scan. That leaves room for variation in clinical judgment and local practice.
2. Different diagnostic rules and thresholds
Countries and clinicians may use different systems, mainly:
- DSM criteria, common in the U.S.
- ICD criteria, historically more restrictive in many countries
Some systems require more...”
This Capsule
“The clue is in the extremes: stimulant prescription rates range from about 1 in 100 children in Hawaii to nearly 1 in 7 in Alabama. The human brain does not mutate that dramatically at state borders. What changes is the machinery around the child: diagnostic thresholds, school incentives, insurance rules, teacher referrals, pharmaceutical marketing, cultural norms, and access to behavioral care.
ADHD may involve real neurodevelopmental differences, but the rate at which those differences become a diagnosis is socially filtered. Several forces drive the variation:
- Diagnosis is behavior-based, not biomarker-based There is no blood test, scan, or “pharmacological litmus test” for ADHD. Diagnosis relies heavily on parent and teacher reports, symptom checklists, and clinician judgment. That makes rates sensitive to local expectations about what counts as “too restless,” ...”
Related in Health
A Patient's Guide to Normal Thyroid Labs and Follow-Up Testing
Normal thyroid lab results do not always explain persistent symptoms such as fatigue, brain fog, cold intolerance, or weight changes. This guide explains what standard thyroid tests can and cannot show, how factors such as antibodies, hormone conversion, reference ranges, and test timing may affect interpretation, and which follow-up tests may be worth discussing with a clinician.
A Buyer's Guide to Health Insurance Costs and Coverage
Picking a health insurance plan during open enrollment is complicated by confusing processes, affordability challenges, and hidden coverage limits. Plans differ widely in how they handle costs, out-of-network care, and quality measures like diabetes management, while support resources vary in funding and availability. Understanding these differences helps you avoid unexpected denials, fees, and gaps in coverage so you can find a plan that truly fits your needs.
Ultra-Processed Foods: Classification, Nutrition, and Public Health Tradeoffs
Ultra-processed has become shorthand for bad, but the label lumps fortified staples in with junk food. These claims challenge the panic from different angles: flaws in the NOVA classification, media oversimplification, and cases where processing genuinely adds nutrition. Reading them equips you to judge food quality past the buzzword.
Menopause Hormone Therapy: Risks, Timing, and Treatment Choices
For women weighing hormone therapy, the stakes are relief from menopause symptoms against feared risks of breast cancer and heart disease. The views split over whether the original risk data was exaggerated, how much the timing of treatment matters, and whether low-dose vaginal estrogen is safer than its warnings suggest. Sort the evidence from the alarm and decide with your doctor what fits your health.